STAAR Surgical Company

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 03:46:08 2024-04-29 pm EDT			5-day change	1st Jan Change
47.42 ^USD	+0.99%		+1.88%	+51.95%

Apr. 11	Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating	MT
Apr. 08	Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating	MT

STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024

April 04, 2024 at 07:00 am EDT

STAAR Surgical Company provided sales guidance for the first quarter ended March 29, 2024. For the period, the company expects Net sales to be in excess of $77 million with U.S. ICL sales expected to be $5 million.

Latest news about STAAR Surgical Company

Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating	Apr. 11	MT
Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating	Apr. 08	MT
STAAR Surgical Shares Jump After Reporting Preliminary Fiscal Q1 Sales	Apr. 04	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday	Apr. 04	MT
STAAR Surgical Reports Preliminary Fiscal Q1 Sales; Updates Fiscal 2024 Sales Outlook -- Shares Jump Pre-Bell	Apr. 04	MT
STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024	Apr. 04	CI
STAAR Surgical Unveils New EVO ICL Data and Latest Innovation for 2024	Apr. 02	CI
STAAR Surgical Company Announces Board Changes	Mar. 12	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Stifel Upgrades STAAR Surgical to Buy From Hold, Raises Price Target to $50 From $30	Mar. 11	MT
Mizuho Securities Adjusts Price Target on STAAR Surgical to $45 From $50, Keeps Buy Rating	Feb. 28	MT
Piper Sandler Cuts STAAR Surgical Price Target to $33 From $40, Maintains Neutral Rating	Feb. 27	MT
STAAR Surgical Q4 Earnings, Revenue Rise	Feb. 26	MT
Transcript : STAAR Surgical Company, Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
STAAR Surgical Company Affirms Earnings Guidance for the Fiscal Year 2024	Feb. 26	CI
STAAR Surgical Company Reports Earnings Results for the Full Year Ended December 29, 2023	Feb. 26	CI
STAAR Surgical Company Reports Earnings Results for the Fourth Quarter Ended December 29, 2023	Feb. 26	CI
Earnings Flash (STAA) STAAR SURGICAL COMPANY Posts Q4 Revenue $76.3M, vs. Street Est of $75.8M	Feb. 26	MT
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
STAAR Surgical Announces Marketing Deal for EVO ICL With SharpeVision	Jan. 23	MT
STAAR Surgical Company Announces Strategic Agreement in U.S. with SharpeVision	Jan. 23	CI
Broadwood Partners Engages in Discussions with STAAR Surgical	Jan. 10	CI
Staar Surgical Company Provides Sales Guidance for the Fiscal 2024	Jan. 08	CI
North American Morning Briefing : Stock Futures -2-	Dec. 06	DJ
Needham Downgrades STAAR Surgical to Hold From Buy	Dec. 05	MT

Chart STAAR Surgical Company

Duration

Period

More charts

Company Profile

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Companyâs EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-07 - Q1 2024 Earnings Call

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for STAAR Surgical Company

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

46.96 USD

Average target price

49.17 USD

Spread / Average Target

+4.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
STAAR SURGICAL COMPANY	+51.95%	2.26B
ABBOTT LABORATORIES	-2.70%	187B
MEDTRONIC PLC	-2.00%	106B
BECTON, DICKINSON AND COMPANY	-4.44%	66.9B
DEXCOM, INC.	+1.03%	49.45B
CENCORA, INC.	+16.48%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+3.21%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+0.78%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution